Global Primary Immunodeficiency Diseases Market $10.2 Billion by 2029

The global market for primary immunodeficiency diseases expected to reach $10.2 billion by 2029, growing at CAGR 6.5% over the forecast period, driven by increasing prevalence and incidence of primary immunodeficiency disorders worldwide.

• Presence of national primary immunodeficiency diseases registries worldwide and increasing healthcare expenditure and government support are the some of the other factors driving the global primary immunodeficiency diseases market.

• Demographic data reported by select physicians presented differences in gender and age [physician-reported regional patients cases or population by Jeffrey Modell Centers Network (JMCN) worldwide].
  • In 2013, patients aged 5–19 years old (38 %), males (57 %), and a total of 62 % of patients identified were in the pediatric age range of less than 1–19 years old were most commonly reported as diagnosed with a primary immunodeficiency.
  • In 2015, Male patients accounted for 58.3 % globally, while female patients accounted for 41.7 %. In the US, 55.7 % of the patients were male and 44.3 % of patients were female. Globally, 63 % of the patients were 19 years of age or younger, while 37 % were 20 years of age or older.

Primary immunodeficiency diseases or disorders (PIDD or PI) are caused as part of the body’s immune system is missing or does not function normally, such that it is an inherited flaw in the immune system that increases the susceptibility to infections.

• Besides susceptibility to infections, PIDD may cause other health problems as well, including allergies, asthma, swollen joints, digestive tract problems, growth problems or an enlarged liver and spleen.
• The technological advances in diagnostics and therapy of primary immunodeficiency are progressing at a fast pace. Research in primary immunodeficiency is making great strides, improving treatment options and enhancing the quality of life for most people with these complex conditions. 
  • Treatment options are targeted toward the specific immune defects and can include transplantation (bone marrow, stem cell, thymus), immunoglobulin (antibody) replacement, preventative antibiotics and strategies to manage autoimmune disease.  Gene therapy has been successful in specific types of PIDD.  
  • Recent developments in molecular studies have allowed the identification of several possible targets for specific therapeutic interventions. Targeted therapies comprise monoclonal antibodies (mAbs) and small molecules, such as cytokines or cytokine inhibitors, employed to up- or down-regulate a particular pathway, depending on the need.
    • They can be used instead of or in combination with traditional immunosuppressant or immunomodulating agents, also as a bridge to definitive treatment, such as hematopoietic stem cell transplantation (HSCT) or gene therapy. 
  • Sequencing in general and next-generation sequencing (NGS) techniques in particular are becoming technically more accurate, fast, affordable and therefore widely available to researchers and physicians.

The global primary immunodeficiency diseases market report estimates the market size ($million 2019 to 2029), market share, growth trends, and forecast (CAGR% 2022 to 2029).

• The market for key segments has been estimated based on epidemiology approach considering patient diagnosis rates, patient treatment rate (IVIG/SCIG), average cost of treatment by regions.
• Global patient surveillance: The distribution of patients diagnosed with PI based on the categories defined by the IUIS Expert Committee for the Classification of PI, predominantly antibody deficiencies are reported by physicians to be 63.4% in the US, 47.7% internationally, and 53% globally.
  • Well-defined Syndromes with Immunodeficiency was 16% in the US, 11.2% internationally, and 12.9% globally. As a percentage of all patients identified with a specific defect, Antibody Deficiencies account for 57% of all patients identified with a specific defect.

The global primary immunodeficiency diseases market segmented by disease or condition [antibody deficiency (Agammaglobulinaemia, common variable immune deficiency, IgG subclass deficiency, SIgAD); cellular immunodeficiency (Ataxia Telangiectasia, DiGeorge syndrome, hyper IgM syndromes, Wiskott-Aldrich syndrome); innate immune disorders (complement deficiencies, and hyper IgE syndrome)], test type (blood and prenatal testing), treatment (immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy)) and geography.

• Based on the disease or conditions, the antibody deficiency segment accounted for the largest share of the total PIDD market, owing to increasing number of patients diagnosed with common variable immune deficiency and selective IgA deficiency.
• In terms of the tests, the blood tests segment dominated the total PID market, and also predicted to grow with the fastest rate during next five years period.
  • Blood test is considered to be the most basic and widely employed laboratory-based technique for the detection of primary immunodeficiency disease.
• By the treatments, the immunoglobulin replacement therapy segment held the largest share of global PID market, being effective, safe, and preferred therapy for the treating primary immune deficiencies.

The highlights of the report include global number of PID patients, by disease (including sub-classes), global number of patient population for treatment or therapy, global number of PID patients, by 15 most commonly identified PIDs by region, and by country, and PID patient’s gender and age by global comparative analysis.

The global market research report is also divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

• Geographically, the global market primary immunodeficiency disease (PIDD or PID or PI) market dominated by the North America and Europe regions, collectively accounting for the majority share of the total PIDD market.
  • Increasing healthcare expenditure, rising awareness about PIDD among the patient population and gradual rise in primary immunodeficiency disorders supports market growth in developed regions.
• On the other hand, the market in the Asia Pacific region expected to expand at the fastest CAGR, due to increased disposable income and rising interest of key companies to expand their presence in the developing countries.

The report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends in strategic management.

Salient Features of the report include:

• Bottom-up research methodology for market size estimation and forecast
• Global number of patient population for PID (subtypes), by country
• Global number of patient population for treatment or therapy, by country
• Global number of PID patients, by 15 most commonly identified PID
• PID patient’s gender and age – global comparative analysis

The major competitors operating in global market for primary immunodeficiency diseases and profiled in the report include Baxter International, Inc., Bio Products Laboratory, Biotest AG, CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, and others.

• Disease / Condition
  • Antibody Deficiency
    • Agammaglobulinaemia
    • Common Variable Immune Deficiency
    • IgG Subclass Deficiency
    • Selective IgA Deficiency (SIgAD)
    • Others
  • Cellular Immunodeficiency
    • Ataxia Telangiectasia
    • DiGeorge Syndrome
    • Hyper IgM Syndromes
    • Wiskott-Aldrich Syndrome
    • Others
  • Innate Immune Disorder
    • Complement Deficiencies
    • Hyper IgE Syndrome
    • Others
• Test Type
  • Blood Testing
  • Prenatal Testing
• Treatment
  • Immunoglobulin Replacement Therapy
  • Antibiotics Therapy
  • Stem cell and Gene Therapy
  • Others
• Geography
  • North America (U.S., Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
  • Asia Pacific (Japan, China, India, Rest of APAC)
  • Latin America (Brazil, Mexico, Rest of LA)
  • Rest of the World
• Company Profiles
  • Baxter International, Inc.
  • Bio Products Laboratory
  • Biotest AG
  • CSL Behring LLC
  • Grifols S.A.
  • Kedrion S.p.A.
  • LFB S.A.
  • Octapharma AG

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/primary-immunodeficiency-diseases-market/

Related publications:

• Primary Immunodeficiency Diseases Market by Disease (Antibody Deficiency – Agammaglobulinaemia, Common Variable Immune Deficiency, IgG Subclass Deficiency, SIgAD; Cellular Immunodeficiency – Ataxia Telangiectasia, DiGeorge Syndrome, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome; Innate Immune Disorders – Complement Deficiencies, and Hyper IgE Syndrome) and Test Types (Blood and Prenatal Testing), and Treatment Types (Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy) and Forecast 2022-2029
• Primary Immunodeficiency Diseases Statistics: Patients, Trends, Market
• Global Urgent Care Center Market $44.2 Billion by 2029
• Global Ambient Assisted Living (AAL) Market $17.5 Billion by 2029
• Immune Checkpoint Inhibitors Market by Drug Type (Brand) – Atezolizumab (Tecentriq, MPDL3280A), Durvalumab (Imfinzi, MEDI4736), Ipilimumab (Yervoy), Nivolumab (Opdivo), Pembrolizumab (Keytruda) and Forecast 2022-2029